Blog/News
November 23, 2023 – Sixty Degree Capital is excited to announce the final close of its third venture capital fund, with $250M earmarked for high-growth companies from Series A to pre-IPO stages across enterprise software and healthcare. Fund III is…
Read More– Plan to initiate the IMAG1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in 2021 August 02, 2021 08:00 ET| Source: T-knife Therapeutics SAN FRANCISCO and BERLIN, Aug. 02, 2021 (GLOBE NEWSWIRE) —…
Read MoreExisting investors NEA, Oak HC/FT and Alta Partners, and new investors, including Endeavor Catalyst, joined the round Funding will accelerate growth, enhance Everside’s technology stack to facilitate predictive, whole-patient care, and support potential M&A opportunities DENVER, July 25, 2022 /PRNewswire/ — Everside Health, LLC, a leading national direct…
Read More— Collaboration Leverages Expertise Across Both Companies, Including Kite’s Global Cell Therapy Leadership and Industry Leading Reliable Manufacturing — SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced…
Read MoreJanuary 09, 2023 02:05 ET| Source: CinCor Pharma IncFollow WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire…
Read More
HAYWARD, Calif.–(BUSINESS WIRE)–RefleXion Medical, a therapeutic oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted the first marketing clearance for its SCINTIX™ biology-guided radiotherapy, a cutting-edge treatment applicable for early and late-stage cancers. The company will host…
Read MorePrograms target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells January 10, 2023 09:00 AM Eastern Standard Time CAMBRIDGE, Mass. & LEVERKUSEN, Germany–(BUSINESS WIRE)–NextPoint Therapeutics, a biotechnology company developing a new world of precision…
Read More
AUTHOR : STRIVE HEALTH DENVER — May 31, 2023 — Strive Health, a national leader in value-based kidney care, has raised $166 million in Series C funding. This funding round was led by NEA alongside five new investors, including large strategic investor…
Read MoreGAITHERSBURG, Md., April 13, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies. The proceeds…
Read MoreDr. Christopher Heery joins as Chief Medical Officer and Neeraj Teotia joins as Chief Commercial Officer GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new…
Read More